Ribomic, Inc.

The achondroplasia market across the seven major markets—the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan—was valued at approximately USD 600 million in 2025 and is expected to grow at a compound annual growth rate of approximately 11% from 2026 to 2036, according to a new report from ResearchAndMarkets.com. The diagnosed prevalent population in these markets was estimated at approximately 28,500 cases in 2025, with the United States representing the largest patient population and commercial market at approximately 14,500 cases. The treatment landscape is shifting toward targeted therapies, with approved drugs VOXZOGO (vosoritide) and YUVIWEL (navepegritide; TransCon CNP) leading the way, while emerging pipeline candidates include infigratinib (BBP-831/BGJ398) from QED Therapeutics, a BridgeBio company, in collaboration with Novartis and Kyowa Kirin, RBM-007 (umedaptanib pegol) from RIBOMIC, and BMN 333 from BioMarin Pharmaceutical. Recent developments include RIBOMIC's Phase II summary and Phase III application in Japan, BridgeBio's positive Phase III PROPEL 3 results for infigratinib, and BioMarin's Phase I data for BMN 333. The report highlights opportunities in earlier genetic diagnosis, targeted FGFR3 therapies, and long-acting CNP analogs, while noting unmet needs such as limited treatment options across age groups and high treatment costs.

Ribomic hit its daily limit up. The company announced it has signed a business partnership agreement with FUJIFILM Toyama Chemical for CDMO services involving lipid nanoparticles utilizing DDS aptamers. Additionally, the National Institutes of Biomedical Innovation, Health and Nutrition, a national research and development agency, will oversee the project starting in fiscal 2026...